AGLE - Aeglea BioTherapeutics Inc Stock Price, Fair Value and News

$27.60-0.08 (-0.29%)

Delayed

Max Portfolio Pct.

Check

Valuation

Check

Stock Quality:

Max Portfolio Pct.

Check

Valuation

Check

AGLE Price Action

AGLE RSI Chart

AGLE Valuation

Market Cap

1.4B

Price/Earnings (Trailing)

-6.58

Price/Sales (Trailing)

276.24

EV/EBITDA

-6.25

Price/Free Cashflow

-9.35

AGLE Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AGLE Fundamentals

AGLE Revenue

Revenue (TTM)

5.1M

Rev. Growth (Yr)

314.39%

Rev. Growth (Qtr)

-12.43%

AGLE Earnings

Earnings (TTM)

-214.9M

Earnings Growth (Yr)

-72.11%

Earnings Growth (Qtr)

-77.74%

AGLE Profitability

EBT Margin

-4196.33%

Return on Equity

-65.64%

Return on Assets

-51.03%

Free Cashflow Yield

-10.69%

AGLE Investor Care

Shares Dilution (1Y)

1170.24%

Diluted EPS (TTM)

-9.25

Revenue & Growth

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	1.4M	1.1M	2.2M	886.0K
2022	20.1M	7.0M	5.8M	2.3M
2021	5.5M	9.9M	14.3M	18.7M
2020	1.5M	1.7M	1.1M	0
2019	0	3.0M	1.2M	0
2018	5.7M	6.6M	5.4M	3.9M
2017	4.8M	4.9M	5.0M	5.2M
2016	6.9M	4.9M	5.0M	4.6M
2015	0	0	0	6.1M

Get all data in R, Python etc through our Historical Stock Data APIs

About Aeglea BioTherapeutics Inc

Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. In addition, its preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.

WEBSITE	aeglea.com
SECTOR	Healthcare
INDUSTRY	Biotechnology
EMPLOYEES	14

Aeglea BioTherapeutics Inc Frequently Asked Questions

What is the ticker symbol for Aeglea BioTherapeutics Inc? What does AGLE stand for in stocks?

AGLE is the stock ticker symbol of Aeglea BioTherapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aeglea BioTherapeutics Inc (AGLE)?

As of Thu Oct 31 2024, market cap of Aeglea BioTherapeutics Inc is 1.41 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AGLE stock?

You can check AGLE's fair value in chart for subscribers.

Is Aeglea BioTherapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AGLE is over valued or under valued. Whether Aeglea BioTherapeutics Inc is cheap or expensive depends on the assumptions which impact Aeglea BioTherapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AGLE.

What is Aeglea BioTherapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Oct 31 2024, AGLE's PE ratio (Price to Earnings) is -6.58 and Price to Sales (PS) ratio is 276.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AGLE PE ratio will change depending on the future growth rate expectations of investors.